Kunshan Xinyunda Biotechnology Co. Ltd. has discovered antibody-drug conjugates (ADCs) consisting of antibodies covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.

Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.

Bivision Pharmaceuticals (Shanghai) Co. Ltd. has identified cyclic peptides targeting fibroblast activating protein α (FAP) reported to be useful for the treatment of cancer.

Researchers from Eurofarma Laboratorios SA and Universidade Federal do Rio de Janeiro – Macae havs synthesized histone deacetylase 6 (HDAC6) inhibitors reported to be potentially useful for the treatment of cancer.

China Pharmaceutical University and Chongqing Innovation Institute China Pharmaceutical University have reported tetrahydronaphthyridine compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists.

Fatty acid lipoxygenase ALOX15 inhibitors have been disclosed in a joint Teijin Pharma Ltd. and Transthera Biosciences Co. Ltd. patent. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, autoimmune disease, cancer, cardiovascular disorders, epilepsy, Parkinson’s disease and allergic rhinitis, among others.

Zhuhai United Laboratories Co. Ltd. has patented boronic acid β-lactamase inhibitors potentially useful for the treatment of bacterial infections.

Impact Therapeutics Inc. has divulged heteroaryl compounds acting as ATP-dependent RNA helicase A (DHX9) inhibitors intended for use in the treatment of cancer.

Indiana Biosciences Research Institute Inc. and Indiana University have jointly identified tyrosine-protein kinase Lyn inhibitors described as potentially useful for the treatment of Alzheimer’s disease.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for the treatment of pain, substance abuse and dependency, schizophrenia, Alzheimer’s disease and sleep disorders.